Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.44 |
| ▸ | KLK1 | P06870 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | DBH | P09172 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12601683 | 0.84 | HTR6 (0.50) | SMN1; SMN2KLKB1KLK1HTR6CYP19A1 | |
| SCHEMBL22533525 | 0.81 | KLKB1 (0.40) | SMN1; SMN2LMNAKLKB1KLK1HTR6 | |
| SCHEMBL29424694 | 0.81 | KLKB1 (0.40) | SMN1; SMN2LMNAKLKB1KLK1HTR6 | |
| SCHEMBL18108931 | 0.76 | YTHDC1 (0.46) | SMN1; SMN2LMNAHTTCYP11B2RAB9A | |
| SCHEMBL29246282 | 0.76 | FGFR1 (0.56) | MAPTTHRBDBH | |
| SCHEMBL30910343 | 0.76 | FGFR1 (0.56) | MAPTTHRBDBH | |
| SCHEMBL956866 | 0.76 | FGFR1 (0.56) | SMN1; SMN2LMNAMAPTTHRBALDH1A1 | |
| SCHEMBL21608523 | 0.76 | RXFP1 (0.36) | SMN1; SMN2LMNAKLKB1KLK1MAPT | |
| SCHEMBL21608265 | 0.75 | CYP17A1 (0.36) | SMN1; SMN2LMNAKLKB1KLK1MAPT | |
| SCHEMBL6085877 | 0.75 | HTR6 (0.53) | SMN1; SMN2LMNAMAPTTHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450343-B2 | Gamma secretase modulators | SCHERING CORPORATION | 2013-05-28 | — | — | US | disclosed |
| US-8450343-B2 | Gamma secretase modulators | SCHERING CORPORATION | 2013-05-28 | — | — | US | disclosed |
| US-8450343-B2 | Gamma secretase modulators | SCHERING CORPORATION | 2013-05-28 | — | — | US | disclosed |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| CN-101939315-A | Gamma secretase modulators | SCHERING CORP | 2011-01-05 | — | — | CN | disclosed |
| EP-2229381-A1 | GAMMA SECRETASE MODULATORS | Schering Corporation (US) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009073777-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | SMN1; SMN2 1580/4885LMNA 2080/4885KLKB1 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.